Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iodixanol
Drug ID BADD_D01178
Description Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents.
Indications and Usage Iodixanol is a contrast agent during coronary angiography.
Marketing Status approved
ATC Code V08AB09
DrugBank ID DB01249
KEGG ID D01474
MeSH ID C044834
PubChem ID 3724
TTD Drug ID D0Y4YG
NDC Product Code 71806-222; 65219-381; 0407-2223; 65219-383; 0407-2222; 57884-0029
UNII HW8W27HTXX
Synonyms iodixanol | Visipaque | Visipaque Unique Softpac | iodixanol-320 | contrast media 2-5410-3
Chemical Information
Molecular Formula C35H44I6N6O15
CAS Registry Number 92339-11-2
SMILES CC(=O)N(CC(CN(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)C)O)C2=C(C(= C(C(=C2I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Adverse event08.06.01.010---
Allergic oedema08.01.07.014; 10.01.03.0250.007113%-
Cardiac disorder02.11.01.003---
Inflammation08.01.05.007; 10.02.01.0890.007113%-
Ischaemia24.04.02.004---
Mental disorder19.07.01.002---
Motor dysfunction15.05.06.006; 17.01.02.031---
Ill-defined disorder08.01.03.049---
Sensation of foreign body08.01.09.0020.017783%-
Obstructive airways disorder22.03.01.0110.007113%-
Renal impairment20.01.03.010---
Anaphylactoid shock10.01.07.004; 24.06.02.005---
Infusion site extravasation08.02.05.007; 12.07.05.0080.024186%
Oropharyngeal discomfort07.05.05.008; 22.12.03.0150.007113%-
Oropharyngeal pain07.05.05.004; 22.12.03.0160.017783%
Anosognosia17.02.03.010; 19.21.01.004---
Acute kidney injury20.01.03.0160.091763%
Toxicity to various agents12.03.01.046---
Drug reaction with eosinophilia and systemic symptoms10.01.01.021; 12.03.01.064; 23.03.05.0050.010670%-
Nasal pruritus22.04.03.0180.015649%-
Dermatitis exfoliative generalised10.01.01.029; 23.03.07.0020.014227%-
Laryngeal discomfort22.12.03.0090.017783%-
Skin plaque23.03.03.0440.010670%-
Blood brain barrier defect17.08.02.028; 24.03.05.0140.014227%-
Contrast media allergy10.01.01.010; 12.02.05.0160.098165%-
Immune thrombocytopenia01.08.01.013; 10.02.01.0830.014227%-
Pharyngeal swelling22.04.05.028---
Swelling of eyelid06.04.04.018; 10.01.05.026; 23.04.01.026---
Symmetrical drug-related intertriginous and flexural exanthema10.01.01.046; 23.03.05.0120.007113%-
Urticaria papular10.01.06.019; 23.04.02.0190.007113%-
The 10th Page    First    Pre   10    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene